[ET Net News Agency, 12 November 2024] UBS raised the target price for China Feihe
(06186) to HKD6.65 from HKD5.10 and maintained the "buy" rating.
The research house said it expects revenue to improve in 2025-26E due to the new birth
rebound in 2024 as the stage 2 and 3 IMF (for 6 month-3 year babies) account for over 70%
of Feihe's sales and the potential rollout of birth allowances. (rc)